Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesa...
Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Berlin/Heidelberg : Springer-Verlag
Subjects
More information
Scope and Contents
Contents
Objective To develop a population pharmacokinetic/pharmacodynamic model describing the relationship between motesanib exposure and tumor response in a phase 2 study of motesanib in patients with advanced differentiated thyroid cancer or medullary thyroid cancer. Methods Data from patients (n = 184) who received motesanib 125 mg once daily were used...
Alternative Titles
Full title
Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_759135354
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_759135354
Other Identifiers
ISSN
0344-5704
E-ISSN
1432-0843
DOI
10.1007/s00280-010-1456-0
